EAP方案治疗晚期胃癌临床疗效观察  

Etoposide,Doxorubicin(or epirubicin) and Cisplatin Regimen in the Treatment of Gastric Adenocarcinoma

作　　者：李峻岭[1] 屈凤莲[1] 崔成旭[1] 王金万[1] 储大同[1] 

机构地区：[1]中国医学科学院中国协和医科大学肿瘤医院

出　　处：《实用癌症杂志》1999年第1期53-54,共2页The Practical Journal of Cancer

摘　　要：为观察ＥＡＰ方案治疗晚期胃癌的疗效和不良反应，采用ＥＡＰ方案（足叶乙甙、阿霉素或表阿霉素、顺铂）治疗胃癌４４例，其中术后辅助性化疗２０例，可评价疗效的有２４例。结果完全缓解２例，部分缓解１１例，总有效率５４．２％。中位生存期为６．５个月（３～３４个月）。化疗的主要不良反应为骨髓抑制及胃肠道反应。结果表明ＥＡＰ在现阶段仍是治疗晚期胃癌较为有效的方案。To evaluate efficacy and safety profile of EAP regimen,44 patients with gastric carcinoma were treated with a combination regimen of etoposide,adriamycin(or epirubicin)and cisplatin(EAP).Among them,20 patients were in post operation adjuvant chemotherapy,another 24 patients were evaluable.The overall response rate was 54.2%(13/24),including 8.3%(2/24) complete response(CR).The median survival time for all patients was 6.5 months(range 3～34 months).Main adverse reactions were myelosuppression and gastrointestinal toxicity.This study shows that EAP regimen is active in the treatment of gastric cancer up date.The adverse reactions are tolerated in the majority of patients.

关 键 词：胃癌 药物疗法 EAP方案 

分 类 号：R735.205[医药卫生—肿瘤] R730.53[医药卫生—临床医学]